Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cetuximab and Lenalidomide in Head and Neck

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT01133665
First received: May 27, 2010
Last updated: November 17, 2014
Last verified: November 2014

May 27, 2010
November 17, 2014
February 2010
August 2011   (final data collection date for primary outcome measure)
Correlate the Presence of Specific Fc RIIIa Polymorphisms With Progression-free Survival in Subjects Receiving Cetuximab and Lenalidomide for SCCHN. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Progression-free survival (PFS) was defined as time from date of the first treatment dose administered to the earlier of disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Correlate the presence of specific Fc RIIIa polymorphisms with progression-free survival in subjects receiving cetuximab and lenalidomide for SCCHN. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01133665 on ClinicalTrials.gov Archive Site
  • Number of Participants With Fatigue Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Maculopapular Rash Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Constipation Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Anemia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Anorexia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Nausea Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Hypoalbuminemia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Lymphopenia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Oral Mucositis Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Pain Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Vomiting Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With White Blood Cell Decreased Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Diarrhea Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Hyponatremia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Neutropenia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Headache Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Hypokalemia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Hypophosphatemia Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Thrombocytopenia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Acneiform Rash Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Hyperglycemia Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Alkaline Phosphatase Increased Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Aspartate Aminotransferase Increased Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Xerostomia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 3
  • Number of Participants With Fever Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Hypocalcaemia Related to Cetuximab/Lenalidomide [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Neck Pain Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Peripheral Sensory Neuropathy Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Alanine Aminotransferase Increased Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Back Pain Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Dyspnea Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Weight Loss Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Blood Bilirubin Increased Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Infusion Related Reaction Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With C. Diff Infection Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Febrile Neutropenia Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
  • Number of Participants With Lymphocyte Count Increased Related to Cetuximab/Lenalidomide [ Time Frame: 24 month ] [ Designated as safety issue: Yes ]
    Toxicity was scored according to NCI/CTC version 4
Incidence of toxicities associated with the combination of cetuximab and lenalidomide given to treat subjects with SCCHN. [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Cetuximab and Lenalidomide in Head and Neck
Phase II Study of Cetuximab and Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.

To study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide. There is evidence with cetuximab in CRC, trastuzumab in breast cancer and rituximab with follicular lymphoma, that FcRIIIa polymorphisms correlate with clinical response to antibody therapy and clinical outcome. It is our hypothesis that patients with SCCHN will have clinical outcomes to cetuximab and lenalidomide that correlate with patient FcRIIIa genotype.

Secondary:

To evaluate the safety and toxicity profile of the combination of cetuximab and lenalidomide given to treat subjects with SCCHN.

To study FcRIIIa polymorphisms and the correlation with the ability of NK cells to mediate ADCC against SCCHN. It is our hypothesis that NK cells from patients with advanced SCCHN can mediate ADCC against SCCHN cell lines in the presence of cetuximab and lenalidomide and that the efficiency of ADCC correlates with FcRIIIa polymorphisms.

To evaluate the ability of NK cells to induce ADCC expression of specific activation markers on the NK cell surface. It is our hypothesis that NK cells that induce ADCC will express specific activation markers that are predictive of efficiency of ADCC.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Squamous Cell Carcinoma
Drug: Cetuximab and Lenalidomide
The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
Experimental: Sub Group 1
All Subjects Enrolled in the Trial
Intervention: Drug: Cetuximab and Lenalidomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
42
August 2012
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent form.
  2. Age ≥18 years at the time of signing the informed consent form.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Recurrent or metastatic squamous cell or undifferentiated carcinoma of the head and neck that is not amenable to curative therapy. Patients who are candidates for local or locoregional therapy should not be deprived of proven beneficial palliative therapies.
  5. All previous cancer therapy, including radiation, hormonal therapy, EGFR inhibitors, and surgery, must have been discontinued at least 4 weeks prior to treatment in this study.
  6. ECOG performance status of 0-1 at study entry.
  7. Laboratory test results within these ranges:

    • Absolute neutrophil count to ≥ 1000/mm³
    • Platelet count ≥ 100,000/mm³
    • Calculated creatinine clearance ≥ 50ml/min by Cockcroft-Gault estimation
    • Total bilirubin < 1.5 x ULN
    • AST (SGOT) and ALT (SGPT) < 3 x ULN or < 5 x ULN if hepatic metastases are present.
  8. Disease free of prior malignancies for < 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast. Patients with malignancies diagnosed less than 3 years prior to study entry are eligible if the first cancer was no greater than stage I and did not recur. Patients with malignancies diagnosed less than 3 years prior to study entry must have the diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck confirmed pathologically.
  9. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
  10. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.
  11. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
  12. Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded), with minimum lesion size ≥ 2 cm on conventional measurement techniques or ≥ 1 cm on spiral computed tomography (CT) scan. Lesions that can be measured clinically must be at least 1 cm in greatest dimension by caliper measurement.

Exclusion Criteria:

  1. Primary head and neck carcinomas of the salivary gland, skin, or thyroid regardless of pathology
  2. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  3. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
  4. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  5. Use of any other experimental drug or therapy within 28 days of baseline.
  6. Prior therapy with lenalidomide for squamous cell carcinoma of the head and neck
  7. Known hypersensitivity to thalidomide.
  8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  9. Concurrent use of other anti-cancer agents or treatments.
  10. Known positive for HIV or infectious hepatitis, type B or C.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01133665
09-206-B
Yes
University of Chicago
University of Chicago
Celgene Corporation
Study Chair: Everett Vokes, M.D. University of Chicago
University of Chicago
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP